Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily

Exclusion Criteria

• •1. Subjects with IOP(Intraocular Pressure) measured at Visit 1 and Visit 2(AM 09:00) above 35 mmHg at more than one eye
• •2. Subjects with a maximum corrected visual acuity of less or than 0.3 in the selected evaluation eye at visit 2
• •3. Subjects who were diagnosed as below with monocular or both eye
• •* Acute or Chronic Closed-Angle Glaucoma
• •* Secondary Glaucoma
• •* Pseudoexfoliation Glaucoma
• •* Neovascular Glaucoma
• •* aphakia
• •* phacocyst capsular torn intraocular lens
• •4. Subjects with significant eye symptoms/signs(Abscesses, diplopia) or severe visual field impairment(Mean Deviation -25dB or more)
• •5. Subjects with severe dry eye syndrome or progressive retinal disease(Retinal degeneration, Diabetic retinopathy, Retinal detachment, Macular edema)
• •6. Subjects with inflammatory/infectious eye disease and active eye disease within the last 3 months
• •7. Subjects who have medical history following
• •* Glaucoma surgery
• •* Subjects with significant history of ocular trauma during the last 6 months, or who underwent surgical ophthalmic surgery
• •* Subjects who received topical or systemic steroids within the last 6 months
• •8. Subjects who wore need to wear contact lenses during the study
• •9. Subjects who have drug interaction with the investigational product, have a significant effect on the intraocular pressure, or who may have an effect on the clinical trial results
• •10. Subjects with known hypersensitivity to investigational product
• •11. Women who are nursing, pregnant or planning pregnancy during the study
• •12. Subjects with bronchial asthma or history
• •13. Subjects who have received any other investigational product within 1 month prior to the first dosing
• •14. Impossible subjects who participate in clinical trial by investigator's decision